symptoms. For example, the antibody therapy may reduce or eliminate the need for therapies such as oral corticosteroids.

In one aspect, the present disclosure refers to use of an anti-TSLP antibody in the manufacture of a medicament for treating corticosteroid-dependent asthma in a subject, wherein the anti-TSLP antibody is to be administered to the subject in a dose of 140 to 420 mg at an interval of every 2 weeks or 4 weeks, wherein the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2, wherein the antibody is an IgG2 antibody.

In another aspect, the present disclosure refers to use of an anti-TSLP antibody in the manufacture of a medicament for treating corticosteroid-dependent asthma in a subject, wherein the anti-TSLP antibody is to be administered to the subject in a dose of 140 to 420 mg at an interval of every 2 weeks or 4 weeks, wherein the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b), wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

In another aspect, the present disclosure refers to use of an anti-TSLP antibody in the manufacture of a medicament for treating corticosteroid-dependent asthma in a subject, wherein the anti-TSLP antibody is to be administered to the subject in a dose of 210 mg at

an interval of every 4 weeks, wherein the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

In another aspect, the present disclosure refers to use of an anti-TSLP antibody in the manufacture of a medicament for treating corticosteroid-dependent asthma in a subject, wherein the anti-TSLP antibody is to be administered to the subject in a dose of 210 mg at an interval of every 4 weeks, wherein the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b), wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

In another aspect, the present disclosure refers to use of an anti-TSLP antibody in the manufacture of a medicament for reducing the frequency of asthma exacerbation in a subject having corticosteroid-dependent asthma, wherein the anti-TSLP antibody is to be administered to the subject in a dose of 140 mg to 420 mg at an interval of every 2 weeks or every 4 weeks, wherein the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1

sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

In another aspect, the present disclosure refers to use of an anti-TSLP antibody in the manufacture of a medicament for reducing the frequency of asthma exacerbation in a subject having corticosteroid-dependent asthma, wherein the anti-TSLP antibody is to be administered to the subject in a dose of 140 mg to 420 mg at an interval of every 2 weeks or every 4 weeks, wherein the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b).

In another aspect, the present disclosure refers to use of an anti-TSLP antibody in the manufacture of a medicament for eliminating the need for oral corticosteroids in a subject with asthma, wherein the anti-TSLP antibody is to be administered to the subject for at least 2 years at a dose of 210 mg at an interval of every 4 weeks, wherein the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

In another aspect, the present disclosure refers to use of an anti-TSLP antibody in the manufacture of a medicament for eliminating the need for oral corticosteroids in a subject with asthma , wherein the anti-TSLP antibody is to be administered to the subject for at least 2 years at a dose of 210 mg at an interval of every 4 weeks, wherein the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b).

In another aspect, the present disclosure refers to use of an anti-TSLP antibody in the manufacture of a medicament for reducing the amount of daily maintenance oral corticosteroids in a subject with asthma to ≤ 5 mg/day, wherein the anti-TSLP antibody is to be administered to the subject for at least 2 years at a dose of 210 mg at an interval of every 4 weeks, wherein the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

In another aspect, the present disclosure refers to use of an anti-TSLP antibody in the manufacture of a medicament for reducing the amount of daily maintenance oral corticosteroids in a subject with asthma to ≤ 5 mg/day, wherein the anti-TSLP antibody is to be administered to the subject for at least 2 years at a dose of 210 mg at an interval of every 4 weeks, the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a

sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b).

[0010] The disclosure provides a method for treating corticosteroid-dependent asthma in a subject comprising administering a therapeutically effective amount of an anti-TSLP antibody or antibody variant in a dose of 140 mg to 420 mg at an interval of every 2 weeks or every 4 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0011] The disclosure provides a method for treating corticosteroid-dependent asthma in a subject comprising administering a therapeutically effective amount of an anti-TSLP antibody or antibody variant in a dose of 140 mg to 420 mg at an interval of every 2 weeks or every 4 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a. a light chain variable domain comprising a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least

80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b), wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0012] The disclosure further provides a method for treating corticosteroid-dependent asthma in a subject comprising selecting a subject in need of treatment for corticosteroid-

dependent asthma and administering a therapeutically effective amount of an anti-TSLP antibody or antibody variant to the subject in a dose of 140 mg to 420 mg at an interval of every 2 weeks or every 4 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0013] Also provided is a method for treating corticosteroid-dependent asthma in a subject comprising selecting a subject in need of treatment for corticosteroid-dependent asthma, administering a therapeutically effective amount of an anti-TSLP antibody or antibody variant to the subject in a dose of 140 mg to 420 mg at an interval of every 2 weeks or every 4 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b), wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0014] In various examples, the light chain variable domain is set out in SEQ ID NO:12 and the heavy chain variable domain is set out in SEQ ID NO:10.

[0015] In various examples, the antibody or antibody variant is administered every 4 weeks.

[0016] In various examples, the antibody or antibody variant is administered at a dose of 210 mg every 2 weeks. In various examples, the antibody or antibody variant is administered at a dose of 210 mg every 4 weeks.

[0017] In various examples, the subject is also receiving treatment with corticosteroids. In various examples the corticosteroids are oral corticosteroids. In various examples, the oral corticosteroids are one or more of prednisone, prednisolone, cortisone, hydrocortisone, methylprednisolone, triamcinolone, betamethasone, dexamethasone, and deflazacort.

[0018] In various examples, the method comprises administering an anti-TSLP antibody or antibody variant in conjunction with an oral corticosteroid, wherein the subject goes through an optimization phase of OCS therapy, a reduction phase of OCS therapy and a maintenance phase of OCS therapy.

[0019] In various examples, the method comprises reducing the dose of corticosteroids when the subject receives a reduction phase of treatment. In various examples, the dose of corticosteroid is reduced every 4 weeks for approximately 20 weeks. In various examples, the dose of corticosteroid is reduced by 5 mg/day or 2.5 mg/day at each reduction interval.

[0020] In various examples, provided is a method for treating corticosteroid-dependent asthma in a subject comprising selecting a subject in need of treatment for oral corticosteroid (OCS)-dependent asthma, administering a therapeutically effective amount of a oral corticosteroid and an anti-TSLP antibody or antibody variant to the subject in a dose of 210 mg at an interval of every 2 weeks or every 4 weeks, wherein the subject receives an optimization phase of OCS therapy, a reduction phase of OCS therapy and a maintenance phase of OCS therapy, and wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0021] The disclosure further provides a method for treating corticosteroid-dependent asthma in a subject comprising selecting a subject in need of treatment oral corticosteroid (OCS)-dependent asthma, administering a therapeutically effective amount of an anti-TSLP antibody or antibody variant to the subject in a dose of 210 mg at an interval of every 2 weeks or every 4 weeks, wherein the subject receives an optimization phase of OCS therapy, a reduction phase of OCS therapy and a maintenance phase of OCS therapy, and wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b), wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0022] In various examples, provided is a method for treating corticosteroid-dependent asthma in a subject comprising selecting a subject in need of treatment for corticosteroid-dependent asthma, administering a therapeutically effective amount of a systemic corticosteroid and an anti-TSLP antibody or antibody variant to the subject in a dose of 210 mg at an interval of every 4 weeks, wherein the subject receives an optimization phase of OCS therapy, a reduction phase of OCS therapy and a maintenance phase of OCS therapy, and wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the

antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0023] The disclosure further provides a method for treating corticosteroid-dependent asthma in a subject comprising selecting a subject in need of treatment of oral corticosteroid (OCS)-dependent asthma, administering a therapeutically effective amount of a systemic corticosteroid and anti-TSLP antibody or antibody variant to the subject in a dose of 210 mg at an interval of every 4 weeks, wherein the subject receives an optimization phase of OCS therapy, a reduction phase of OCS therapy and a maintenance phase of OCS therapy, and wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b), wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0024] In various examples, the light chain variable domain is set out in SEQ ID NO:12 and the heavy chain variable domain is set out in SEQ ID NO:10.

[0025] In various examples, the optimization phase comprises a dose of OCS of 30 mg/day, 25 mg/day, 20 mg/day, 15 mg/day, 10 mg/day, 7.5 mg/day or 5 mg/day.

[0026] In various examples, the reduction phase comprises a dose of OCS of 25 mg/day, 20 mg/day, 15 mg/day, 10 mg/day, 7.5 mg/day, 5 mg/day, 2.5 mg/day or 0 mg/day.

[0027] In various examples, the maintenance phase comprises a dose of OCS of 15 mg/day, 10 mg/day, 7.5 mg/day, 5 mg/day, 2.5 mg/day or 0 mg/day.

[0028] In various examples, the anti-TSLP antibody variant has substantially similar pK characteristics as tezepelumab-ekko in humans.

[0029] In various examples, the antibody or antibody variant is administered for a period of at least 4 months, 6 months, 9 months, 1 year, 2 years or more.

[0030] In various examples, the anti-TSLP antibody or antibody variant thereof is bivalent and selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a recombinant antibody, an antigen-binding antibody fragment, a single chain antibody, a monomeric antibody, a diabody, a triabody, a tetrabody, a Fab fragment, an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, and an IgG4 antibody.

[0031] In one example, the anti-TSLP antibody variant is selected from the group consisting of a diabody, a triabody, a tetrabody, a Fab fragment, a single domain antibody, an scFv, wherein the dose is adjusted such that the binding sites are equimolar to those dosed by bivalent antibodies.

[0032] In various examples, the antibody is an IgG2 antibody.

[0033] In one example, the antibody or antibody variant is a human antibody.

[0034] In various examples, the antibody is tezepelumab. In various examples, the tezepelumab is an IgG2 antibody having the full length heavy and light chain amino acid sequences set out in SEQ ID NOs: 13 and 14, respectively.

[0035] In various examples, the antibody or antibody variant is administered to the subject in a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient.

[0036] In various examples, the corticosteroid-dependent asthma is in a subject with severe asthma.

[0037] In various examples, the antibody is tezepelumab or another anti-TSLP antibody described in the art. Exemplary antibodies are described further in the Detailed Description.

[0038] In various examples, the subject is an adult. In various examples, the subject is a child or adolescent.

[0039] In various examples, the administration reduces frequency of or levels of administered corticosteroids in the subject. In various examples, the corticosteroids are oral corticosteroids. In various examples, the oral corticosteroids are selected from the group consisting of prednisone, prednisolone, cortisone, hydrocortisone, methylprednisolone, triamcinolone, betamethasone, dexamethasone, and deflazacort.

[0040] In various examples, the reduction of levels of corticosteroids is reduction from baseline in daily maintenance OCS compared to baseline in a subject having corticosteroid dependent asthma comprising wherein the reduction is 90% to 100% reduction, 75% to 90%

reduction, 0% to 75% reduction, or 30% to 50% reduction. In various examples, the method results in discontinued OCS without loss of asthma control.

[0041] In various examples, the administration reduces frequency of or levels of co-administered therapy in the subject. Optionally, the co-administered therapy is inhaled corticosteroids (ICS), long-acting β2 agonist (LABA), leukotriene receptor antagonists (LTRA), long-acting anti-muscarinics (LAMA), cromones, short- acting β2 agonist (SABA), and theophylline. In various examples, the inhaled corticosteroids are selected from the group consisting of beclomethasone dipropionate, beclomethasone diproprionate, ciclesonide, fluticasone furoate, (Arnuity® Ellipta®), fluticasone propionate, budesonide, mometasone furoate, mometasone furoate, beclomethasone dipropionate (e.g., Fostair®), fluticasone propionate (e.g., Seretide®, Advair®), fluticasone furoate (e.g., Relvar® Ellipta®, Breo® Ellipta®), budesonide (e.g., Symbicort®), and mometasone furoate (e.g., Dulera®).

[0042] It is further provided that administration of the anti-TSLP antibody or antibody variant decreases levels of Th2 cytokines in the subject.

[0043] In various examples, administration of the anti-TSLP antibody or antibody variant improves one or more measures of corticosteroid dependent asthma in a subject selected from the group consisting of forced expiratory volume (FEV), FEV_1 reversibility, forced vital capacity (FVC), FeNO, Asthma Control Questionnaire-6 score and AQLQ(S)+12 score, change from baseline in pre-BD FEV_1, reduction from baseline in daily maintenance OCS dose, daily maintenance OCS dose ≤ 5 mg, and ≥ 50% reduction from baseline in daily maintenance OCS dose, asthma exacerbations as measured by AAER, time to first asthma exacerbation, rate of asthma exacerbations associated with emergency room (ER) visit, urgent care visit or hospitalization, and proportion of participants who did not experience an asthma exacerbation, weekly mean home PEF (morning and evening), and/or St George's Respiratory Questionnaire (SGRQ) score. It is further provided that the administration reduces the incidence of adrenal insufficiency in a subject.

[0044] In one example, the administration improves one or more symptoms of asthma as measured by an asthma symptom diary.

[0045] In various examples, treatment with anti-TSLP antibody or antibody variant modulates the levels of one or more biomarkers of corticosteroid-dependent asthma, including, cytokines, IgE, CCL17, CCL18, CCL22, and RNA transcriptional changes in nasal epithelium. In various examples, treatment with anti-TSLP reduces the level of Th2 cytokines. In various examples, the treatment modulates (reduces or moderates) levels

stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b).

[0055] In various examples, the light chain variable domain is set out in SEQ ID NO:12 and the heavy chain variable domain is set out in SEQ ID NO:10.

[0056] In various examples, the antibody is tezepelumab.

[0057] In various examples, the antibody or antibody variant is administered every 4 weeks. In various examples, the antibody or antibody variant is administered at a dose of 210 mg every 2 weeks. In various examples, the antibody or antibody variant is administered at a dose of 210 mg every 4 weeks.

[0058] In various examples, the methods comprise administering anti-TSLP antibody or antibody variant in conjunction with an oral corticosteroid, wherein the subject goes through an optimization phase of OCS therapy, a reduction phase of OCS therapy and a maintenance phase of OCS therapy.

[0059] In various examples, the disclosure provides a method for eliminating the need for oral corticosteroids in a subject having corticosteroid dependent asthma comprising administering to the subject a therapeutically effective amount of an anti-TSLP antibody or antibody variant for at least 2 years at a dose of 210 mg at an interval of every 4 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0060] In various examples, the disclosure provides a method for eliminating the need for oral corticosteroids in a subject having corticosteroid dependent asthma comprising administering to the subject a therapeutically effective amount of an anti-TSLP antibody or antibody variant for at least 2 years at a dose of 210 mg at an interval of every 4 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a light chain variable domain selected from the group consisting of: i. a sequence

of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b).

[0061] In various examples, the disclosure provides a method for reducing the amount of daily maintenance oral corticosteroids in a subject having corticosteroid dependent asthma to ≤ 5 mg/day comprising administering to the subject a therapeutically effective amount of an anti-TSLP antibody or antibody variant for at least 2 years at a dose of 210 mg at an interval of every 4 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0062] In various examples, the disclosure provides a method for reducing the amount of daily maintenance oral corticosteroids in a subject having corticosteroid dependent asthma to ≤ 5 mg/day comprising administering to the subject a therapeutically effective amount of an anti-TSLP antibody or antibody variant for at least 2 years at a dose of 210 mg at an interval of every 4 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide

consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b).

[0063] In various examples, the light chain variable domain is set out in SEQ ID NO:12 and the heavy chain variable domain is set out in SEQ ID NO:10.

[0064] It is provided that the dosing and antibody and antibody variant types referenced above apply to each method described herein.

[0065] In various examples, the antibody or antibody variant is administered to the subject in a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient.

[0066] In various examples, the administration delays the time to a corticosteroid-dependent asthma exacerbation compared to a subject not receiving the anti-TSLP antibody.

[0067] In various examples, the administration reduces frequency of or levels of co-administered therapy in the subject. Optionally, the co-administered therapy is dupilumab, immunosuppressive or immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, interferon (IFN)-gamma, Janus kinase inhibitors, azathioprine, methotrexate), anti-IL-13 antibodies, anti-IL-5 pathway antibodies (benralizumab, mepolizumab, reslizumab), or combinations thereof.

[0068] In various examples, the administration eliminates the need for corticosteroid therapy.

[0069] In various examples, the administration is subcutaneous or intravenous.

[0070] In various examples, the antibody is tezepelumab or another anti-TSLP antibody described in the art, e.g., in Table A. Exemplary antibodies are described further in the Detailed Description.

[0071] Also provided is an anti-TSLP antibody or antibody variant for use in the methods described herein.

[0072] In one example, the disclosure provides an anti-TSLP antibody or antibody variant for use in the treatment of corticosteroid-dependent asthma in a subject comprising

administering a therapeutically effective amount of a dose of 140 mg to 420 mg at an interval of every 2 weeks or every 4 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0073] Also provided is the use of an anti-TSLP antibody or antibody variant for the manufacture of a medicament for use in the methods described herein.

[0074] In one example, the disclosure provides the use of an anti-TSLP antibody or antibody variant for the manufacture of a medicament for use in the treatment of corticosteroid-dependent asthma in a subject comprising administering a therapeutically effective amount of a dose of 140 mg to 420 mg at an interval of every 2 weeks or every 4 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0075] It is understood that each feature or embodiment, or combination, described herein is a non-limiting, illustrative example of any of the aspects of the disclosure and, as such, is meant to be combinable with any other feature or embodiment, or combination, described herein. For example, where features are described with language such as “one embodiment”, “some embodiments”, “certain embodiments”, “further embodiment”, “specific exemplary embodiments”, and/or “another embodiment”, each of these types of

embodiments is a non-limiting example of a feature that is intended to be combined with any other feature, or combination of features, described herein without having to list every possible combination. Such features or combinations of features apply to any of the aspects of the disclosure. Where examples of values falling within ranges are disclosed, any of these examples are provided as possible endpoints of a range, any and all numeric values between such endpoints are provided, and any and all combinations of upper and lower endpoints are envisioned.

[0076] The headings herein are for the convenience of the reader and not intended to be limiting. Additional aspects, embodiments, and variations of the disclosure will be apparent from the Detailed Description and/or Drawings and/or claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0077] Figure 1 depicts the oral corticosteroid titration schema.

[0078] Figures 2A and 2B show estimated daily doses for inhaled corticosteroids. Figure 2C shows estimated OCS dose therapy equivalence.

[0079] Figure 3 shows the reductions from baseline (week 0) in daily OCS dose in patients originally from NAVIGATOR and SOURCE over time in the DESTINATION study.

[0080] Figures 4A-4B show mean daily OCS dose in the tezepelumab and placebo group at week 104 in patients from NAVIGATOR (Figure 4A) and in patients from SOURCE (Figure 4B).

[0081] Figure 5. Sequences of anti-TSLP antibody tezepelumab.

[0082] Figure 6 depicts an example OCS dose titration schedule during the OCS reduction and maintenance phase.

[0083] Figure 7A shows the proportion of patients receiving a maintenance OCS dose of ≤ 5 mg/day. Data are presented as the number of patients with a maintenance OCS dose ≤ 5 mg/day divided by the number of patients who reached the time point. Figure 7B shows the proportions of patients with ≥ 50% reduction in OCS dose. Data are presented as the number of patients with ≥ 50% reduction in OCS dose divided by the number of patients who reached the time point.

[0084] Figure 8 shows the proportion of patients who discontinued maintenance daily OCS. Data are presented as the number of patients who discontinued OCS divided by the number of patients who reached the time point.

What is Claimed:

1. Use of an anti-TSLP antibody in the manufacture of a medicament for treating corticosteroid-dependent asthma in a subject, wherein the anti-TSLP antibody is to be administered to the subject in a dose of 140 to 420 mg at an interval of every 2 weeks or 4 weeks, wherein the antibody comprises

a. a light chain variable domain comprising:

i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

b. a heavy chain variable domain comprising:

i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2, wherein the antibody is an IgG2 antibody.

2. Use of an anti-TSLP antibody in the manufacture of a medicament for treating corticosteroid-dependent asthma in a subject, wherein the anti-TSLP antibody is to be administered to the subject in a dose of 140 to 420 mg at an interval of every 2 weeks or 4 weeks, wherein the antibody comprises

a. a light chain variable domain selected from the group consisting of:

i. a sequence of amino acids at least 80% identical to SEQ ID NO:12;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and

b. a heavy chain variable domain selected from the group consisting of:

i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b), wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

3. The use of claim 1 or 2, wherein the light chain variable domain is set out in SEQ ID NO:12 and the heavy chain variable domain is set out in SEQ ID NO:10.

4. The use of any one of claims 1 to 3, wherein the antibody is to be administered every 2 weeks or every 4 weeks.

5. The use of any one of claims 1 to 4, wherein the antibody is an IgG2 antibody.

6. The use of any one of claims 1 to 5, wherein the antibody is to be administered at a dose of 210 mg.

7. The use of any one of claims 1 to 6, wherein the antibody is tezepelumab.

8. Use of an anti-TSLP antibody in the manufacture of a medicament for treating corticosteroid-dependent asthma in a subject, wherein the anti-TSLP antibody is to be administered to the subject in a dose of 210 mg at an interval of every 4 weeks, wherein the antibody comprises

a. a light chain variable domain comprising:

i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

b. a heavy chain variable domain comprising:

i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

9. Use of an anti-TSLP antibody in the manufacture of a medicament for treating corticosteroid-dependent asthma in a subject, wherein the anti-TSLP antibody is to be administered to the subject in a dose of 210 mg at an interval of every 4 weeks, wherein the antibody comprises

a. a light chain variable domain selected from the group consisting of:

i. a sequence of amino acids at least 80% identical to SEQ ID NO:12;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and

b. a heavy chain variable domain selected from the group consisting of:

i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b), wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

10. The use of claim 8 or 9, wherein the light chain variable domain is set out in SEQ ID NO:12 and the heavy chain variable domain is set out in SEQ ID NO:10.

11. The use of any one of the preceding claims, wherein the antibody is to be administered for a period of at least 4 months, 6 months, 9 months, 1 year, 2 years or more.

12. The use of any one of the preceding claims, wherein said anti-TSLP antibody is bivalent and selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a recombinant antibody, an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, and an IgG4 antibody.

13. The use of any one of claims 8 to 12, wherein the antibody is an IgG2 antibody.

14. The use of any one of claims 6 to 11, wherein the antibody is tezepelumab.

15. The use of any one of the preceding claims, wherein the antibody is a human antibody.

16. The use of any one of the preceding claims wherein, the antibody is to be administered to the subject in a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient.

17. The use of any one of the preceding claims, wherein the corticosteroid-dependent asthma is severe or asthma.

18. The use of any one of the preceding claims, wherein the corticosteroid-dependent asthma is oral corticosteroid-dependent asthma.

19. The use of any one of the preceding claims, wherein the subject is an adult.

20. The use of any one of the preceding claims, wherein the subject is a child or adolescent.

21. The use of any one of the preceding claims, wherein the administration improves one or more measures of corticosteroid-dependent asthma selected from the group consisting of forced expiratory volume (FEV), FEV_1 reversibility, forced vital capacity (FVC), FeNO, Asthma Control Questionnaire (ACQ)-6 score and AQLQ(S)+12 score, change from baseline in pre-BD FEV_1, reduction from baseline in daily maintenance OCS dose, daily maintenance OCS dose ≤ 5 mg, and ≥ 50% reduction from baseline in daily maintenance OCS dose, asthma exacerbations, as measured by AAER and time to first asthma exacerbation, rate of asthma exacerbations associated with emergency room (ER) visit, urgent care visit or hospitalization, and proportion of participants who did not experience an asthma exacerbation, weekly mean home PEF (morning and evening), adrenal insufficiency, and/or St George's Respiratory Questionnaire (SGRQ) score.

22. The use of any one of the preceding claims, wherein the administration improves one or more symptoms of corticosteroid dependent asthma as measured by a patient symptom diary.

23. The use of any one of the preceding claims, wherein the antibody is to be administered every 4 weeks.

24. The use of any one of the preceding claims, wherein the antibody is tezepelumab.

25. The use of claim 24, wherein the antibody is an IgG2 antibody, and has the full length heavy and light chain sequences set out in SEQ ID NOs: 13 and 14, respectively.

26. The use of any one of the preceding claims, wherein the antibody variant has substantially similar pK characteristics as tezepelumab-ekko in humans.

27. Use of an anti-TSLP antibody in the manufacture of a medicament for reducing the frequency of asthma exacerbation in a subject having corticosteroid-dependent asthma, wherein the anti-TSLP antibody is to be administered to the subject in a dose of 140 mg to 420 mg at an interval of every 2 weeks or every 4 weeks, wherein the antibody comprises

a. a light chain variable domain comprising:

i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

b. a heavy chain variable domain comprising:

i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

28. Use of an anti-TSLP antibody in the manufacture of a medicament for reducing the frequency of asthma exacerbation in a subject having corticosteroid-dependent asthma, wherein the anti-TSLP antibody is to be administered to the subject in a dose of 140

mg to 420 mg at an interval of every 2 weeks or every 4 weeks, wherein the antibody comprises

a. a light chain variable domain selected from the group consisting of:

i. a sequence of amino acids at least 80% identical to SEQ ID NO:12;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and

b. a heavy chain variable domain selected from the group consisting of:

i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b).

29. The use of claim 27 or 28, wherein the light chain variable domain is set out in SEQ ID NO:12 and the heavy chain variable domain is set out in SEQ ID NO:10.

30. The use of any one of claims 27 to 29, wherein the antibody is to be administered every 4 weeks.

31. The use of any one of claims 27 to 30, wherein the antibody is to be administered at a dose of 210 mg.

32. The use of any one of claims 27 to 31, wherein the antibody is to be administered for a period of at least 4 months, 6 months, 9 months, 1 year, 2 years or more.

33. The use of any one of claims 27 to 32, wherein said anti-TSLP antibody is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a recombinant antibody, an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, and an IgG4 antibody.

34. The use of any one of claims 27 to 33, wherein the antibody is an IgG2 antibody.

35. The use of any one of claims 27 to 34, wherein the antibody is a human antibody.

36. The use of any one of claims 27 to 35, wherein the antibody is tezepelumab.

37. The use of any one of claims 27 to 36, wherein the antibody is to be administered to the subject in a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient.

38. The use of any one of claims 27 to 37, wherein the administration delays the time to asthma exacerbation compared to a subject not receiving the anti-TSLP antibody.

39. The use any one of claims 27 to 38, wherein the administration reduces frequency of or levels of co-administered therapy in the subject.

40. The use of claim 39, wherein the administration eliminates the need for oral corticosteroid therapy or inhaled corticosteroid therapy.

41. The use of any one of claims 27 to 40, wherein the dose of corticosteroids the subject receives is to be reduced during a reduction phase of treatment and the subject is to be kept on a maintenance dose of corticosteroids.

42. The use of claim 41, wherein the dose of corticosteroid is to be reduced every 4 weeks for approximately 20 weeks.

43. The use of claim 41 or 42, wherein the dose of corticosteroid is to be reduced by 5 mg/day or 2.5 mg/day.

44. Use of an anti-TSLP antibody in the manufacture of a medicament for eliminating the need for oral corticosteroids in a subject with asthma, wherein the anti-TSLP antibody is to be administered to the subject for at least 2 years at a dose of 210 mg at an interval of every 4 weeks, wherein the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

45. Use of an anti-TSLP antibody in the manufacture of a medicament for eliminating the need for oral corticosteroids in a subject with asthma , wherein the anti-TSLP antibody is to be administered to the subject for at least 2 years at a dose of 210 mg at an interval of every 4 weeks, wherein the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b).

46. Use of an anti-TSLP antibody in the manufacture of a medicament for reducing the amount of daily maintenance oral corticosteroids in a subject with asthma to ≤ 5 mg/day, wherein the anti-TSLP antibody is to be administered to the subject for at least 2 years at a dose of 210 mg at an interval of every 4 weeks, wherein the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

47. Use of an anti-TSLP antibody in the manufacture of a medicament for reducing the amount of daily maintenance oral corticosteroids in a subject with asthma to ≤ 5 mg/day, wherein the anti-TSLP antibody is to be administered to the subject for at least 2 years at a dose of 210 mg at an interval of every 4 weeks, the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of

amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b).

48. The use of any one of claims 44 to 47 wherein the light chain variable domain is set out in SEQ ID NO:12 and the heavy chain variable domain is set out in SEQ ID NO:10.

49. The use of any one of claims 27 to 48, wherein the anti-TSLP antibody is tezepelumab.

50. The use of claim 49, wherein the antibody is an IgG2 antibody, and has the full length heavy and light chain sequences set out in SEQ ID NOs: 13 and 14, respectively.

51. The use of any one of claims 27 to 50, wherein the subject has oral corticosteroid-dependent asthma.

52. The use of any one of the preceding claims, wherein the administration is subcutaneous or intravenous.